CorMedix Inc.

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
4.18 ^USD	-1.65%		-3.46%	+11.17%

28/05	CorMedix Shares Rise on Multiyear DefenCath Supply Deal	MT
28/05	CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider	CI

CorMedix Inc. Announces Resignation of Gary A. Gelbfish as a Member of the Board of Directors

January 17, 2019 at 02:57 am IST

CorMedix Inc. announced that Gary A. Gelbfish, MD FACS has resigned his position as a member of the Board of Directors, effective January 14, 2019.

Latest news about CorMedix Inc.

CorMedix Shares Rise on Multiyear DefenCath Supply Deal	28/05	MT
CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider	28/05	CI
Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
CorMedix's DefenCath Now Commercially Available For US Inpatient Use	15/04	MT
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	15/04	CI
Sector Update: Health Care Stocks Decline Late Afternoon	09/04	MT
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization	08/04	MT
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC	08/04	CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon	13/03	MT
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says	13/03	MT
RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	13/03	MT
Transcript : CorMedix Inc., Q4 2023 Earnings Call, Mar 12, 2024	12/03
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
North American Morning Briefing : Inflation Data -2-	12/03	DJ
CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath	31/01	CI
Cormedix Inc. Announces Commercial and Operational Updates	08/01	CI
CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts	15/12	CI
CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023	15/12	CI
CorMedix Inc. Announces Partnership with The Leapfrog Group	04/12	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	16/11	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	16/11	MT
Sector Update: Health Care	16/11	MT
CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients	15/11	CI

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.18 USD

Average target price

13 USD

Spread / Average Target

+211.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORMEDIX INC.	+11.17%	23Cr
KYOWA KIRIN CO. LTD.	+17.03%	910.9Cr
SK BIOPHARMACEUTICALS CO., LTD.	-24.00%	443.59Cr
YUHAN CORPORATION	+13.37%	423.81Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+31.17%	403.4Cr
INDIVIOR PLC	+7.76%	214.27Cr
BETTA PHARMACEUTICALS CO., LTD.	-34.04%	190.17Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.56%	194.47Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-47.93%	162.57Cr

Specialty & Advanced Pharmaceuticals

CorMedix Inc.

Equities

CRMD

US21900C3088

Pharmaceuticals

CorMedix Inc. Announces Resignation of Gary A. Gelbfish as a Member of the Board of Directors

Latest news about CorMedix Inc.

Chart CorMedix Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals